Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
Since bed rotting isnt on your bingo card, lets talk about why protein matters, how much you actually need, and which options work best for GLP-1 users, plus a few easy ways to hit your goals without forcing huge meals or living in the kitchen
At LCS Medical Spa, our medical professionals are here to support you, and we can adjust your dose or provide personalized recommendations to ensure your treatment is as comfortable and effective as possible
The side effect timeline: Week 1-2: Nausea is most common, usually mild to moderate
.png?sfvrsn=1e7191c0_3)
